Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | egf-like domain protein | 0.0421 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0421 | 0.5 | 0.5 |
Echinococcus multilocularis | Tolloid protein 1 | 0.0421 | 0.5 | 0.5 |
Echinococcus multilocularis | fibrillin 1 | 0.0421 | 0.5 | 0.5 |
Onchocerca volvulus | Arrow homolog | 0.0421 | 0.5 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0421 | 0.5 | 0.5 |
Echinococcus granulosus | Tolloid protein 1 | 0.0421 | 0.5 | 0.5 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0421 | 0.5 | 0.5 |
Echinococcus multilocularis | laminin | 0.0421 | 0.5 | 0.5 |
Echinococcus granulosus | laminin | 0.0421 | 0.5 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0421 | 0.5 | 0.5 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.0421 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0421 | 0.5 | 0.5 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0421 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0421 | 0.5 | 0.5 |
Brugia malayi | Fibulin-1 precursor | 0.0421 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0421 | 0.5 | 0.5 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0421 | 0.5 | 0.5 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0421 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0421 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = -19.4 % | In vivo hepatic cholesterol synthesis inhibitory activity in male Sprague-Dawley rat after oral administration of the compound at a concentration of 2.0 mg/kg | ChEMBL. | 11392538 |
Inhibition (functional) | = -19.4 % | In vivo hepatic cholesterol synthesis inhibitory activity in male Sprague-Dawley rat after oral administration of the compound at a concentration of 2.0 mg/kg | ChEMBL. | 11392538 |
Inhibition (functional) | = 21.8 % | In vivo hepatic cholesterol synthesis inhibitory activity in male Sprague-Dawley rat after oral administration of the compound at a concentration of 0.2 mg/kg | ChEMBL. | 11392538 |
Inhibition (functional) | = 21.8 % | In vivo hepatic cholesterol synthesis inhibitory activity in male Sprague-Dawley rat after oral administration of the compound at a concentration of 0.2 mg/kg | ChEMBL. | 11392538 |
Relative potency (binding) | = 1 | In vitro HMG-CoA reductase inhibitory activity required to inhibit cellular steroidgenesis in Hep G2 cells (human hepatoma cell line) with pravastatin as reference compound | ChEMBL. | 11392538 |
Relative potency (binding) | = 1 | In vitro HMG-CoA reductase inhibitory activity required to inhibit cellular steroidgenesis in Hep G2 cells (human hepatoma cell line) with pravastatin as reference compound | ChEMBL. | 11392538 |
Relative potency (binding) | = 6 | In vitro rat HMG-CoA reductase inhibitory activity required to inhibit sterol synthesis in cell free system with pravastatin as reference compound | ChEMBL. | 11392538 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.